Dieterich, Walburga; Schuppan, Detlef; Schink, Monic et al.
Influence of low FODMAP and gluten-free diets on disease activity and intestinal microbiota in patients with non-celiac gluten sensitivityCLINICAL NUTRITION. Bd. 38. H. 2. 2019 S. 697-707
Caminero, Alberto; McCarville, Justin L.; Zevallos, Victor F. et al.
Lactobacilli Degrade Wheat Amylase Trypsin Inhibitors to Reduce Intestinal Dysfunction Induced by Immunogenic Wheat ProteinsGASTROENTEROLOGY. Bd. 156. H. 8. 2019 S. 2266-2280
Elli, Luca; Ferretti, Francesca; Orlando, Stefania et al.
Management of celiac disease in daily clinical practiceEUROPEAN JOURNAL OF INTERNAL MEDICINE. Bd. 61. 2019 S. 15-24
Fritscher-Ravens, Annette; Pflaum, Theresa; Moesinger, Marie et al.
Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin EGASTROENTEROLOGY. Bd. 157. H. 1. 2019 S. 109-+
Fernandez, Alberto Caminero; McCarville, Justin; Zevallos, Victor F. et al.
METABOLISM OF WHEAT AMYLASE TRYPSIN INHIBITORS BY LACTOBACILLI AMELIORATES GUT DYSFUNCTION INDUCED BY WHEAT PROTEINSGASTROENTEROLOGY. Bd. 156. H. 6. 2019 S. S174-S175
Farrell, Geoff; Schattenberg, Jorn M.; Leclercq, Isabelle et al.
Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic SteatohepatitisHEPATOLOGY. Bd. 69. H. 5. 2019 S. 2241-2257
Kaps, Leonard; Nuhn, Lutz; Choteschovsky, Niklas et al.
NANOPARTICULAR BISPHOSPHONATE TO SELECTIVELY TARGET AND REPOLARIZE LIVER MACROPHAGES FOR ANTI-FIBROTIC RESPONSES IN experimental LIVER FIBROSISHEPATOLOGY. Bd. 70. 2019 S. 1127A-1127A
Kaps, Leonard; Schuppan, Detlef; Nuhn, Lutz et al.
Nanoparticular bisphosphonate to selectively target and repolarize liver macrophages for efficient anti-tumour responseJOURNAL OF HEPATOLOGY. Bd. 70. H. 1. 2019 S. E366-E367
Neumann, Jan; Ziegler, Kira; Gelleri, Marton et al.
Nanoscale distribution of TLR4 on primary human macrophages stimulated with LPS and ATINANOSCALE. Bd. 11. H. 19. 2019 S. 9769-9779
Yang, Ai Ting; Kim, Yong Ook; Aslam, Misbah et al.
New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progresion in CCL4 induced liver fibrosis, but not in MDR2-/- miceJOURNAL OF HEPATOLOGY. Bd. 70. H. 1. 2019 S. E206-E206